Stoke Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenue of $13.8 million for the quarter, a substantial increase from $4.8 million in the same period last year. For the six months ended June 30, 2025, revenue reached $172.4 million, compared to $9.0 million for the first half of 2024. This growth is primarily attributed to the company's collaboration agreements with Biogen and Acadia Pharmaceuticals, with notable contributions of $150.8 million from the Biogen agreement and $16.8 million from Acadia.
Despite the increase in revenue, Stoke Therapeutics reported a net loss of $23.5 million for the second quarter of 2025, slightly improved from a loss of $25.7 million in the same quarter of 2024. For the first half of 2025, the company achieved a net income of $89.4 million, a significant turnaround from a loss of $52.1 million in the prior year. The company's operating expenses also rose, totaling $41.1 million for the second quarter, up from $34.2 million in the previous year, driven by increased research and development costs associated with its clinical programs.
In terms of strategic developments, Stoke Therapeutics has made notable progress in its clinical programs, particularly with its lead candidate, zorevunersen (STK-001), which is in late-stage clinical testing for Dravet syndrome. The company initiated a Phase 3 study, EMPEROR, in May 2025, with the first patient dosed in August 2025. Additionally, the company is advancing its second candidate, STK-002, for the treatment of autosomal dominant optic atrophy (ADOA), with plans to begin a Phase 1 study in the second half of 2025.
Operationally, Stoke Therapeutics reported a cash position of $355 million as of June 30, 2025, which the company believes will fund its operations through mid-2028. The company has not yet generated product sales, relying instead on collaboration agreements and equity offerings for funding. The filing indicates that the company expects to continue incurring losses as it invests in research and development, with plans to expand its clinical trials and commercial infrastructure. Looking ahead, Stoke Therapeutics remains focused on advancing its product candidates through regulatory approval and commercialization, while also navigating the challenges of funding and market conditions.
About Stoke Therapeutics, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.